DavidMWaterhouseMD

Oncology • Cincinnati, OH

Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Waterhouse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Waterhouse's full profile

Already have an account?

Office
4350 Malsbary Rd
Cincinnati, OH 45242
Phone+1 513-751-2273

Fax+1 513-792-5844
Is this information wrong?

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1989 - 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1985 - 1988
University of Massachusetts Medical SchoolClass of 1985

Certifications & Licensure

OH State Medical License 1993 - 2025
MA State Medical License 1986 - 2024
KY State Medical License 1997 - 2018
MI State Medical License 1989 - 1996
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Completed
Phase 2
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
Recruiting
Phase 2
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Start of enrollment: 2020 Mar 11
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
A call to action to advance patient-focused and decentralized clinical trials.
R Donald Harvey, Therica M Miller, Patricia A Hurley, Ramya Thota, Lora J Black, Suanna S Bruinooge, Leigh M Boehmer, Mark E Fleury, Jasmine Kamboj, Mujahid A Rizvi, B...> ;Cancer. 2024 Apr 15
Sotorasib in KRASmutated lung cancer - Authors' reply.
Paz-Ares, L., Mehta, B., Wang, Y., de Langen, A., Obiozor, C., Waterhouse, D.> ;Lancet. 2024 Jan 13
Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
David M Waterhouse, Patrick Ward, David R Drosick, Caleb Burdette, Daniel Davies, Molly A Mendenhall> ;JCO Oncology Practice. 2023 Nov 1
Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.
David Waterhouse, Candice Yong, Andrew Frankart, Lance Brannman, Tiernan Mulrooney, Nicholas Robert, Kathleen M Aguilar, Juliet Ndukum, Ion Cotarla> ;Future Oncology. 2023 Sep 1
Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based Practice.
Molly A Mendenhall, Andrew Guinigundo, Dan Davies, Patrick Ward, David R Drosick, David M Waterhouse> ;JCO Oncology Practice. 2024 Feb 1
1 citations
Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non-Small-Cell Lung Cancer in a Large Community Oncology Practice.
David M Waterhouse, Patrick Ward, Suzzette Arnal, Marcus Neubauer, David R Drosick, Dan Davies, Molly A Mendenhall> ;JCO Oncology Practice. 2023 Jun 1
7 citations
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony...> ;Journal of Thoracic Oncology. 2023 Jul 1
70 citations
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASmutation: a randomised, open-label, phase 3 trial.
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schuler, Hervé Lena, Ferd...> ;Lancet. 2023 Mar 4
3 citations
Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer.
Rachel B Jimenez, Caroline Schenkel, Laura A Levit, Bonnie Hu, Xiudong Jennifer Lei, R Donald Harvey, Vicki A Morrison, Teri Pollastro, David Waterhouse, Colin Weekes,...> ;JCO Oncology Practice. 2022 Nov 1
4 citations
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
David Waterhouse, Laura Iadeluca, Sneha Sura, Keith Wilner, Birol Emir, Stan Krulewicz, Janet Espirito, Lauren Bartolome> ;Targeted Oncology. 2022 Jan 1
12 citations
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry.
Kathryn Finch Mileham, Suanna S. Bruinooge, Charu Aggarwal, Alicia L. Patrick, Christiana Davis, Daniel J Mesenhowski, Alexander I. Spira, Eric J. Clayton, David M. Wa...> ;JCO Oncology Practice. 2021 Oct 25
3 citations
Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset
David M. Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon Lubinga, David D. Stenehjem> ;Data in Brief. 2021 Jun 6
60 citations
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
David M. Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon Lubinga, David D. Stenehjem> ;Lung Cancer. 2021 Jun 1
17 citations
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.
David M. Waterhouse, Wan-Yu Tseng, Janet L. Espirito, Nicholas J. Robert> ;Clinical Lung Cancer. 2021 May 29
11 citations
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy.
David D. Stenehjem, Solomon Lubinga, Keith A. Betts, Wenxi Tang, Mads Jenkins, Yong Yuan, John Hartman, Sumati Rao, Jenny Lam, David M. Waterhouse> ;Future Oncology. 2021 Apr 14
2 citations
Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
David M. Waterhouse, E. Nwokeji, Marley Boyd, John R. Penrod, Janet L. Espirito, Nicholas J. Robert, M. Daumont> ;Future Oncology. 2021 Mar 26
252 citations
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei, Scott N. Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro Carpeño, Adam Pluzanski, Oscar Arrieta, Osvaldo Arén Fro...> ;Journal of Clinical Oncology. 2021 Jan 15
3 citations
Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement
Dax Kurbegov, Patricia Hurley, David M. Waterhouse, Nicholas J. Robert, Grzegorz S. Nowakowski, Michael A. Thompson, Suanna S. Bruinooge, Richard L. Schilsky, Leslie B...> ;JCO Oncology Practice. 2021 Jan 6
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
Matthew Z Guo, Kristen A. Marrone, Alexander Spira, David M. Waterhouse, Susan C Scott> ;Oncotargets and Therapy. 2021 Jan 1
91 citations
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen A. Hussein, Robert M. Jotte, Leora Horn, Davey B. Daniel, George P. Keogh, Ben C. Creela...> ;Journal of Clinical Oncology. 2020 Sep 10
12 citations
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
David M. Waterhouse, Janet L. Espirito, Marc D. Chioda, Bismark Baidoo, Jack Mardekian, Nicholas J. Robert, Elizabeth T. Masters> ;Drugs - Real World Outcomes. 2020 Dec 1
64 citations
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Raj Parikh, Rishi Ja...> ;Clinical Cancer Research. 2020 Sep 15
129 citations
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncol...
David M. Waterhouse, R. Donald Harvey, Patricia Hurley, Laura A. Levit, Edward S. Kim, Heidi D. Klepin, Kathryn Finch Mileham, Grzegorz S. Nowakowski, Caroline Schenke...> ;JCO Oncology Practice. 2020 May 12
25 citations
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squam...
David R. Spigel, Dianna Shipley, David M. Waterhouse, Suzanne F. Jones, Patrick J. Ward, Kent C. Shih, Brian Hemphill, Michael McCleod, Robert C. Whorf, Ray D. Page, J...> ;The Oncologist. 2019 Dec 1
11 citations
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small...
Jonathan W. Goldman, David M. Waterhouse, Ben George, Peter J. O'Dwyer, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Karen Kelly> ;Frontiers in Oncology. 2019 Nov 26
Join now to see all

Press Mentions

OHC's Waterhouse Feels Privileged to Share in Oncology Patients’ Highs and LowsFebruary 26th, 2021
Oncology Care Model Supports Practice & Benefits Medicare's Bottom LineOctober 23rd, 2019
Increasing Biomarker Testing Rates for Patients with NSCLCDecember 9th, 2023